Detection of HER-2/neu, c-myc amplification and p53 inactivation by FISH in Egyptian patients with breast cancer.
Breast cancer is a leading cause of cancer-related deaths in women worldwide. The clinical course of this disease is highly variable and clinicians continuously search for prognostic parameters that can accurately predict prognosis, and indicate a suitable adjuvant therapy for each patient. Amplification of the two oncogenes HER-2/neu and c-myc and inactivation of the tumor suppressor gene p53 are frequently encountered in breast carcinomas. The purpose of this study was to use the fluorescence in situ hybridization (FISH) for the assessment of HER-2/neu and c-myc amplification and p53 inactivation and to relate these molecular markers with the commonly used clinical and pathological factors. The study was conducted on 34 tissue samples obtained from 33 females and 1 male with breast carcinomas and 17 samples obtained from 16 females and 1 male with benign breast lesions. Results revealed that the level of HER-2/neu, c-myc and p53 in the malignant group was significantly increased as compared to the benign group. On relating the level of the molecular markers to clinicopathological factors, p53 was significantly associated with increased patient's age. The sensitivity of the investigated markers significantly increased with larger tumor size. Concerning tumor grade, HER-2/neu and p53 showed a significant increase in low-grade tumors whereas c-myc showed a highly significant increase in high-grade tumors. With regard to disease staging, HER-2/neu and c-myc were the only markers that showed significant increase at late stages of disease. p53 and HER-2/neu were significantly associated with positive lymph nodal status. A significant correlation was obtained between the levels of the three biomarkers to each other. Conclusively, the combination of HER-2/neu, c-myc and p53 can stratify patients into different risk groups.
Ismail
Manal F
MF
Department of Biochemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Aly
Magdy Sayed
MS
Khaled
Hussein M
HM
Mohamed
Hanaa M
HM
D000293:Adolescent; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis; D001706:Biopsy; D001943:Breast Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000235:genetics*; D018567:Breast Neoplasms, Male / Q000175:diagnosis / Q000453:epidemiology / Q000235:genetics; D004534:Egypt / Q000453:epidemiology; D005260:Female; D006801:Humans; D017404:In Situ Hybridization, Fluorescence / Q000379:methods*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging / Q000379:methods; D021141:Nucleic Acid Amplification Techniques / Q000379:methods; D015995:Prevalence; D016271:Proto-Oncogene Proteins c-myc / Q000032:analysis* / Q000235:genetics; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis* / Q000235:genetics; D016159:Tumor Suppressor Protein p53 / Q000032:analysis* / Q000235:genetics; D055815:Young Adult
D014408:Biomarkers, Tumor; D016271:Proto-Oncogene Proteins c-myc; D018719:Erb-b2 Receptor Tyrosine Kinases; D016159:Tumor Suppressor Protein p53; C489427:MYC protein, human; C508053:ERBB2 protein, human
Oncogene. 1996 Jul 4;13(1):63-72
8700555
Breast Cancer Res. 2005;7(6):R1058-79
16457687
Breast Cancer Res Treat. 2002 Jul;74(1):25-31
12150449
Breast Cancer Res. 2005;7(5):R598-604
16168103
Breast J. 2005 Nov-Dec;11(6):433-9
16297088
Genes Chromosomes Cancer. 1998 Oct;23(2):100-8
9739012
Cancer Res. 2005 Mar 1;65(5):1909-17
15753390
Hum Pathol. 2005 Jun;36(6):634-9
16021569
Oncogene. 1999 May 13;18(19):3004-16
10378696
Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5321-5
1351679
Science. 1987 Jan 9;235(4785):177-82
3798106
J Natl Cancer Inst. 1998 Sep 2;90(17):1262-9
9731732
Nature. 1986 Feb 27-Mar 5;319(6056):783-4
3005871
Hua Xi Yi Ke Da Xue Xue Bao. 1998 Dec;29(4):399-401
10743237
Hum Pathol. 1998 Apr;29(4):323-9
9563780
Breast Cancer Res Treat. 2000 Feb;59(3):211-21
10832591
Indian J Pathol Microbiol. 2004 Jul;47(3):340-2
16295419
Oncol Rep. 2005 Apr;13(4):633-41
15756435
Int J Biol Markers. 2006 Jul-Sep;21(3):131-40
17013794
Acta Oncol. 2000;39(3):327-33
10987229
Diagn Mol Pathol. 2007 Dec;16(4):207-10
18043283
J Clin Pathol. 2006 Apr;59(4):424-8
16497871
Histopathology. 2005 Apr;46(4):431-41
15810955
Br J Cancer. 2004 Apr 19;90(8):1612-9
15083194
Cancer Res. 2002 Mar 1;62(5):1481-8
11888924
Clin Exp Metastasis. 2005;22(6):495-502
16320112
J Pathol. 2004 Aug;203(4):918-26
15258994
Int J Oncol. 2006 Oct;29(4):973-80
16964393
Cancer. 2005 Mar 1;103(5):900-5
15643600
Am J Clin Pathol. 1999 Oct;112(4):459-69
10510669
Tumour Biol. 2001 Sep-Oct;22(5):337-44
11553865
Rev Med Chir Soc Med Nat Iasi. 2004 Jul-Sep;108(3):657-61
15832994
Int J Cancer. 2001 Jul 20;95(4):266-70
11400121
Nature. 1992 Jul 2;358(6381):15-6
1614522
Oncologist. 2006 Sep;11(8):857-67
16951389
Oncogene. 2000 Dec 11;19(53):6093-101
11156522
Am J Pathol. 2000 Jan;156(1):183-91
10623666
Histopathology. 1991 Nov;19(5):403-10
1757079
Cancer Res. 2006 May 15;66(10):5330-7
16707459
Oncogene. 2000 Dec 11;19(53):6102-14
11156523
Indian J Exp Biol. 2000 Mar;38(3):225-30
10927863
Curr Opin Genet Dev. 1995 Feb;5(1):97-104
7749333
Endocr Relat Cancer. 2000 Sep;7(3):143-64
11021963
Cancer. 2003 Feb 1;97(3):690-4
12548612
Am J Clin Pathol. 2004 Aug;122(2):246-55
15323142
Cell Growth Differ. 1993 Jan;4(1):41-7
8424905
J Pathol. 1995 Nov;177(3):225-32
8551383
Ann Oncol. 2000 Jun;11(6):647-63
10942052
Breast Cancer Res Treat. 1998 May;49(1):35-9
9694609